Verve Therapeutics to Participate in Upcoming Investor Conferences

Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in fireside chats during the following investor conferences:

• Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1 p.m. ET in New York, NY
• Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 8 a.m. ET in Miami Beach, FL

Live webcasts will be available in the investor section of the company's website at www.vervetx.com, and will be archived for 30 days following the fireside chats.

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally-tolerated standard of care therapies. For more information, please visit www.VerveTx.com.

Investor ContactJen RobinsonVerve Therapeutics, [e-mail]

Media ContactAshlea [e-mail]